The prevalence of ALK and ROS1 mutations in NSCLC patients is 2–7% and 1–2%, respectively, with the mutations only occurring in 1.2% of patients enrolled in the current study. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.